Provexis (PXS) AI Stock Analysis

• Market Cap: £15.54M
• Dividend Yield: N/A
• Average Volume (3M): 309.72K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.03
• Revenue Growth: 100.60%
• EPS Growth: N/A
• Country: UK
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 2,345,891,400
• 10 Day Avg. Volume: 136,513
• 30 Day Avg. Volume: 309,718
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: ―

Provexis demonstrates notable revenue growth and a strong balance sheet with no debt, but struggles with profitability and cash flow challenges. Technical indicators show positive momentum, which provides some optimism. However, the negative P/E ratio and absence of dividend yield suggest caution in its valuation. Overall, the stock reflects moderate potential, with significant risks in financial performance.

Provexis Business Overview & Revenue Model

Company Description

Provexis PLC is a biotechnology company based in the United Kingdom that focuses on the research, development, and commercialization of functional foods, medical foods, and dietary supplements. The company's flagship product is Fruitflow, a natural, scientifically-proven ingredient that promotes healthy blood flow and is used in a variety of food and dietary supplement products globally. Provexis operates primarily in the nutraceutical sector, aiming to provide innovative, science-backed solutions to enhance cardiovascular health.

How the Company Makes Money

Provexis makes money primarily through the commercialization of its Fruitflow technology. The company generates revenue by licensing Fruitflow to manufacturers and distributors in the food and dietary supplement industries, allowing them to incorporate the ingredient into their products. Additionally, Provexis engages in collaborative partnerships and agreements with other companies to co-develop and market new products that incorporate its proprietary technology. These partnerships often involve upfront payments, milestone payments, and royalties based on product sales. The company's focus on intellectual property and innovation ensures a recurring revenue stream through licensing deals and collaborative ventures.

Provexis Financial Statement Overview

Summary

Provexis shows promising revenue growth but struggles with profitability and cash flow. The balance sheet remains robust with no debt, offering some financial stability. However, the company must address cash flow inefficiencies and manage operational costs to improve its financial health and sustainability in the long run.

Income Statement

The company has shown significant revenue growth, with a 105.68% increase from the previous year. However, profitability remains a concern with consistent net losses. The gross profit margin is 35.38%, indicating some efficiency in managing production costs, but the net profit margin is negative at -73.10%, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows strong equity, with a debt-to-equity ratio of 0, indicating no financial leverage. The equity ratio stands at 145.48%, demonstrating a strong capital base relative to total assets. However, decreased stockholders' equity over the years suggests potential concerns about future capital sustainability.

Cash Flow

Cash flow analysis indicates a challenging situation with negative free cash flow growth, highlighting cash outflows exceeding inflows. The operating cash flow to net income ratio is 0.33, suggesting inefficient cash conversion from net income. The company needs to improve cash generation from operations.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	1.20M	801.96K	389.92K	426.17K	505.33K	347.94K
Gross Profit	419.48K	283.80K	294.42K	380.05K	456.19K	312.15K
EBITDA	-326.69K	-603.59K	0.00	0.00	0.00	0.00
Net Income	-478.29K	-586.24K	-385.24K	-224.25K	-341.01K	-406.23K
Balance Sheet
Total Assets	822.39K	498.04K	845.99K	1.13M	1.29M	468.76K
Cash, Cash Equivalents and Short-Term Investments	478.20K	189.36K	379.12K	863.87K	1.08M	291.33K
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	471.01K	307.45K	188.34K	157.91K	150.68K	150.08K
Stockholders Equity	885.14K	724.34K	1.19M	1.50M	1.66M	814.37K
Cash Flow
Free Cash Flow	-112.82K	-191.50K	-519.85K	-213.79K	-262.32K	-334.64K
Operating Cash Flow	-112.82K	-191.50K	-519.85K	-213.54K	-262.07K	-334.64K
Investing Cash Flow	1.46K	1.73K	887.00	78.00	-250.00	399.00
Financing Cash Flow	270.74K	0.00	35.10K	1.05M	1.05M	300.33K

Provexis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PXS, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.71, and above the 200-day MA of 0.63, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 34.01 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PXS.

Provexis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OXB	65 Neutral	£657.40M	-15.65	-75.71%	―	55.44%	75.77%
PXS	55 Neutral	£15.54M	―	-51.21%	―	100.60%	―
NANO	44 Neutral	£17.80M	-6.53	―	―	-8.06%	-132.47%
FAB	44 Neutral	£20.74M	-10.20	―	―	72.98%	55.36%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Provexis Corporate Events

Provexis Grants Options and Warrants to CEO and Consultants

Provexis plc announced the grant of 56,000,000 options and 58,730,000 warrants over ordinary shares to its CEO, Ian Ford, and to certain scientific, sales, and marketing consultants. This move follows discussions with the company’s larger shareholders and is aimed at aligning management and consultant incentives with company performance, potentially impacting up to 10% of the company’s issued share capital. The grant of options to Ian Ford is a related party transaction, with the directors, excluding Ford, deeming the terms fair and reasonable for shareholders.